PARK2 Gene, Parkin
Pathway Diagram
Mermaid diagram (expand to render)
Introduction
Park2 Parkin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@luck2020]
| Attribute | Value | [@mata2021]
|-----------|-------| [@pickrell2015]
| Gene Symbol | PARK2 | [@trempe2013]
| Full Name | Parkin RBR E3 Ubiquitin Protein Ligase |
| Chromosomal Location | 6q26 |
| NCBI Gene ID | [5071](https://www.ncbi.nlm.nih.gov/gene/5071) |
| Ensembl ID | [ENSG00000185345](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185345) |
| UniProt ID | [O60260](https://www.uniprot.org/uniprot/O60260) |
| OMIM | [602544](https://www.omim.org/entry/602544) |
| Gene Family | RING finger family, RBR family |
| Protein Class | E3 ubiquitin ligase |
</div>}
Overview
The PARK2 gene encodes Parkin, a RING-between-RING (RBR) family E3 ubiquitin ligase that plays a critical role in mitochondrial quality control through mitophagy[@kitada1998]. Parkin is one of the most frequently mutated genes in autosomal recessive juvenile Parkinsonism (AR-JP), accounting for approximately 50% of familial PD cases and up to 20% of early-onset PD[@luck2020]. The protein is encoded by 12 exons spanning 1.4 Mb of genomic DNA, making it one of the largest Parkinson's disease genes[@mata2021]. Parkin functions as a key regulator of mitochondrial homeostasis, targeting damaged mitochondria for degradation via the autophagy-lysosome pathway[@pickrell2015].
Molecular Function
Protein Structure
Parkin contains several functional domains:
| Domain | Position | Function |
|--------|----------|----------|
| Ubl domain | N-terminus (1-76) | Ubiquitin-like, auto-inhibition |
| RING0 | 141-217 | E2 binding, catalytic |
| RING1 | 237-328 | Ubiquitin transfer |
| IBR | 329-380 | Between RINGs |
| RING2 | 418-465 | Catalytic, Cys431 active site |
| REP | 466-494 | Repressor element |
E3 Ubiquitin Ligase Activity
Parkin catalyzes ubiquitin transfer through a unique mechanism:
E2 Binding: RING1 domain binds ubiquitin-conjugating enzyme (E2)
Thioester Intermediate: Catalytic Cys431 forms thioester with ubiquitin
Substrate Targeting: RING2 recruits specific substrates
Ubiquitin Transfer: Substrate Lys residue receives ubiquitinSubstrates and Functions
| Substrate | Ubiquitin Linkage | Function |
|-----------|------------------|----------|
| Mito proteins | K63, K27 | Mitophagy receptor |
| Pael-R | K48 | Proteasomal degradation |
| Synphilin-1 | K48, K63 | Protein aggregation |
| p53 | K48 | [Apoptosis](/entities/apoptosis) regulation |
| VDAC1 | K63 | Mitochondrial pore |
| Tomm20 | K27, K63 | Mitophagy |
Expression Pattern
Brain
- Substantia Nigra Pars Compacta: High expression in dopaminergic [neurons](/entities/neurons)
- Striatum: Moderate expression
- [Hippocampus](/brain-regions/hippocampus): Pyramidal neurons
- Cerebral [Cortex](/brain-regions/cortex): Layer-specific expression
The [Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=PARK2) shows PARK2 expression in dopaminergic neurons of the substantia nigra and pyramidal neurons in the hippocampus and cortex.
Peripheral Tissues
- Heart: High expression
- Skeletal Muscle: Moderate expression
- Kidney: Low expression
- Pancreas: Low expression
Disease Associations
Parkinson's Disease
PARK2 mutations are the most common cause of autosomal recessive juvenile Parkinsonism (AR-JP)[@luck2020]:
- Prevalence: ~50% of familial AR-JP cases
- Inheritance: Autosomal recessive
- Onset: Typically before age 20
- Phenotype: Early motor fluctuations, tremor, dystonia
- Progression: Slower progression than idiopathic PD
Mutation Types
| Mutation Type | Examples | Frequency |
|--------------|----------|-----------|
| Deletions | Exon deletions | 30-40% |
| Missense | R42P, C250F, T415N | 20-30% |
| Nonsense | Q34X, R245X | 10-15% |
| Splice site | IVS1+1G>A | 5-10% |
Pathogenic Mechanisms
Mitochondrial Dysfunction: Impaired mitophagy leads to accumulation of damaged mitochondria
Oxidative Stress: Increased [ROS](/entities/reactive-oxygen-species) from defective mitochondria
Protein Aggregation: Impaired clearance of misfolded proteins
Dopaminergic Vulnerability: Neuronal death due to energy failureTherapeutic Implications
Gene Therapy Approaches
| Strategy | Approach | Status |
|----------|----------|--------|
| AAV-PARK2 | Wild-type gene delivery | Preclinical |
| Small Molecule Activators | Parkin activators | Discovery |
| [Autophagy](/entities/autophagy) Enhancers | [mTOR](/entities/mtor)-independent | Preclinical |
Drug Development
- Parkin activators: Identifying compounds that enhance E3 ligase activity
- Mitochondrial protectants: Targeting downstream effects
- Antioxidants: Counteracting oxidative stress
Animal Models
Knockout Models
- Parkin⁻/⁻ mice: No spontaneous neurodegeneration, altered dopamine metabolism
- Parkin⁻/⁻ zebrafish: Developmental defects, mitochondrial dysfunction
Transgenic Models
- Human PARK2 transgenic: Variable expression, rescue of KO phenotypes
- Mutant PARK2: Modeling patient mutations
Disease Models
- MPTP + Parkin KO: Enhanced vulnerability to mitochondrial toxins
- α-Syn + Parkin KO: Synergistic protein aggregation
Research Directions
Biomarkers
- Parkin activity assays: Measuring E3 ligase function
- Mitochondrial function: Live-cell imaging of mitophagy
- Genetic testing: Comprehensive mutation screening
Therapeutic Targets
- E3 ligase modulators: Small molecules enhancing activity
- Substrate-specific inhibitors: Blocking toxic substrate interactions
- Gene therapy vectors: Optimized CNS delivery
Key Publications
[@kitada1998] Kitada T, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605-608. PMID: 9560156(https://pubmed.ncbi.nlm.nih.gov/9560156/)<br>
[@luck2020] Luck CB, et al. PARK2 mutations in Parkinson's disease. J Neurol. 2020;267(10):2865-2875. PMID: 32613488(https://pubmed.ncbi.nlm.nih.gov/32613488/)<br>
[@mata2021] Mata IF, et al. Parkin: a multipurpose neuroprotective agent? Expert Opin Ther Targets. 2021;25(4):283-296. PMID: 33945312(https://pubmed.ncbi.nlm.nih.gov/33945312/)<br>
[@pickrell2015] Pickrell AM, et al. Beyond the mitochondrion: cytosolic PINK1 recruits parkin to regulate mitophagy. J Cell Biol. 2015;209(2):175-176. PMID: 25901683(https://pubmed.ncbi.nlm.nih.gov/25901683/)<br>
[@trempe2013] Trempe JF, et al. Structure of parkin reveals mechanisms for activation. Cell. 2013;152(4):818-830. PMID: 23352246(https://pubmed.ncbi.nlm.nih.gov/23352246/)<br>
Background
The study of Park2 Parkin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Data
Single-cell RNA sequencing data from the Allen Brain Atlas shows PARK2 expression:
- Substantia nigra pars compacta: Moderate expression in dopaminergic neurons
- Cerebral cortex: Low to moderate expression across cortical layers
- Hippocampus: Moderate expression in pyramidal neurons and dentate gyrus
- Cerebellum: Low expression in Purkinje cells and granule cells
- Basal ganglia: Moderate expression in striatal medium spiny neurons
Key observations:
- PARK2 is widely expressed across multiple brain regions
- Expression is higher during development and decreases with age
- The gene is expressed in both neurons and astrocytes
- Loss of PARK2 leads to early-onset autosomal recessive Parkinson's disease
External Resources:
- [Allen Brain Atlas - PARK2 Expression](https://portal.brain-map.org/)
- [Allen Cell Type Atlas - PARK2 in Neurons](https://celltypes.brain-map.org/)
See Also
- [Proteins Index](/proteins)
- [Parkin Protein](/entities/parkin-protein)
- [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [PINK1 Gene](/genes/pink1)
- PRKN Gene
- [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-pathology)
- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosome-neurodegeneration)
External Links
- [NCBI Gene: PARK2](https://www.ncbi.nlm.nih.gov/gene/5071)
- [UniProt: PARK2](https://www.uniprot.org/uniprot/O60260)
- [Ensembl: PARK2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185345)
- [OMIM: PARK2](https://www.omim.org/entry/602544)
- [PDGene: PARK2](https://www.pdgene.org/geneoverview?geneid=5071)
Structural Biology of Parkin
Domain Architecture
Parkin is a 465-amino acid protein with a complex domain architecture [@trempe2013]:
- Ubiquitin-like (Ubl) domain (residues 1-76): Located at the N-terminus, this domain is non-covalently associated with the catalytic core and functions in substrate recognition. The Ubl domain adopts a β-grasp fold similar to ubiquitin and can be autoubiquitinated.
- RING0 domain (residues 141-217): A unique RING-like element not found in other RING finger proteins. RING0 contains the "RING-helix-RING" motif and is essential for E2 enzyme binding.
- RING1 domain (residues 237-328): Mediates binding to UBC7 and other E2 enzymes. Contains the canonical C3H2C3 RING finger motif with zinc-coordinating cysteine residues.
- In-between-RING (IBR) domain (residues 329-380): A unique structural element positioned between RING1 and RING2. The IBR contributes to substrate recognition and proper positioning of the RING domains.
- RING2 domain (residues 418-465): Contains the catalytic cysteine (Cys431) that forms a thioester intermediate with ubiquitin during the ubiquitination reaction.
Auto-Inhibition Mechanism
Parkin exists in an auto-inhibited state under normal conditions [@bhandari2021]:
Ubl domain interaction: The Ubl domain binds to the RING0-RING1-IBR region, blocking substrate access
Phosphorylation block: Key serine residues prevent activation
E2 binding obstruction: The auto-inhibitory conformation prevents E2 enzyme engagementPINK1 phosphorylation relieves this auto-inhibition, allowing parkin activation.
Structural Changes Upon Activation
PINK1-mediated phosphorylation triggers major conformational changes:
- Ubl domain release: Phosphorylation disrupts the inhibitory Ubl-RING interaction
- RING domain repositioning: The catalytic domains become accessible
- E2 recruitment: Activated parkin can now bind E2 enzymes
- Catalytic activation: Cys431 becomes active for ubiquitin transfer
Parkin in Mitochondrial Quality Control
The PINK1-Parkin Pathway
The PINK1-Parkin pathway is the canonical mechanism for mitochondrial quality control [@geisler2010]:
Mitochondrial damage detection: In healthy mitochondria, PINK1 is imported and degraded. In damaged mitochondria, PINK1 accumulates on the outer membrane.
PINK1 activation: Mitochondrial damage leads to PINK1 autophosphorylation and activation.
Parkin recruitment: Phosphorylated PINK1 recruits parkin to the outer mitochondrial membrane [@narendra2008].
Parkin activation: PINK1 phosphorylates parkin's Ubl domain (Ser65), triggering conformational activation [@vives2010].
Ubiquitination: Activated parkin ubiquitinates outer membrane proteins, marking mitochondria for degradation.
Mitophagy: Ubiquitinated mitochondria are recognized by autophagosomal receptors and delivered to lysosomes.Substrate Selection
Parkin exhibits broad substrate specificity [@suggests2023]:
| Substrate | Ubiquitin Linkage | Cellular Function |
|-----------|-------------------|-------------------|
| VDAC1 | K63 | Mitochondrial porin, mitophagy receptor |
| Mito proteins | K27, K63 | Mitophagy tagging |
| MFN1/2 | K48, K63 | Mitochondrial fusion |
| Tomm20 | K27, K63 | Import receptor |
| MIRO1/2 | K63 | Mitochondrial motility |
| HTRX2 | K63 | Mitochondrial quality control |
| Synphilin-1 | K48, K63 | Protein aggregation |
| Pael-R | K48 | ER-associated degradation |
Mitochondrial Dynamics Regulation
Parkin modulates mitochondrial dynamics through multiple mechanisms [@youle2013]:
- Fusion inhibition: Ubiquitination of MFN1/2 promotes their degradation, reducing fusion
- Fission promotion: Parkin supports fission by clearing damaged components
- Biogenesis coordination: Links quality control to mitochondrial biogenesis
Parkin and Synaptic Function
Presynaptic Role
Parkin is localized to presynaptic terminals where it regulates [@taylor2022]:
- Synaptic vesicle pools: Parkin maintains functional synaptic vesicle reserves
- Neurotransmitter release: Regulates vesicle release probability
- Synaptic protein turnover: Controls synaptic protein quality
Postsynaptic Functions
In dendrites and postsynaptic compartments:
- Dendritic mitochondrial support: Ensures energy supply for synaptic activity
- Postsynaptic density organization: Maintains synaptic structure
- Spine morphology: Regulates dendritic spine development
Synaptic Dysfunction in PD
Loss of parkin function leads to synaptic deficits:
- Reduced vesicle recycling: Impaired neurotransmitter release
- Altered plasticity: Defects in LTP and LTD
- Synuclein accumulation: Failed clearance at synapses
Parkin in Neuroinflammation
Immune Regulation
Parkin modulates neuroinflammatory responses [@lee2020]:
- Microglial activation: Regulates microglial inflammatory responses
- Cytokine production: Controls pro-inflammatory cytokine expression
- NF-κB signaling: Parkin limits excessive inflammation
Peripheral Immune Interactions
Parkin affects peripheral immune cells:
- T cell function: Modulates adaptive immune responses
- Macrophage polarization: Influences M1/M2 balance
- Cytokine clearance: Helps resolve inflammation
Parkin Mutations and Phenotypic Spectrum
Common Pathogenic Mutations
| Mutation | Type | Domain | Effect |
|----------|------|--------|--------|
| R42P | Missense | Ubl | Disrupts Ubl fold |
| C250F | Missense | RING1 | Impairs E2 binding |
| T415N | Missense | RING1 | Reduces activity |
| C289G | Missense | IBR | Structural defect |
| D280N | Missense | RING2 | Catalytic defect |
Genotype-Phenotype Correlations
Different mutation types produce varying phenotypes [@ibanez2022]:
- Exon deletions: Often cause complete loss of function, severe phenotype
- Missense mutations: Variable severity, residual activity correlates with onset
- Compound heterozygotes: Variable presentation
Atypical Presentations
Beyond classic AR-JP, parkin mutations cause:
- Late-onset PD: Some missense mutations cause milder disease
- Dystonia: Early-onset generalized dystonia
- Cognitive involvement: Some patients develop dementia
Small Molecule Activators
Developing parkin-activating compounds:
- E3 ligase enhancers: Increase catalytic activity
- Allosteric activators: Target regulatory domains
- PINK1 enhancers: Upstream pathway activation
Gene Therapy Approaches
Viral vector delivery of functional PARK2:
- AAV vectors: Engineered for CNS delivery
- Promoter selection: Neuron-specific expression
- Dosing optimization: Balancing efficacy and safety
Protein-Based Therapies
- Recombinant parkin protein: Delivery challenges
- Peptide mimetics: Bypassing delivery issues
- Enzyme replacement: Experimental approaches
Combination Strategies
- Gene therapy + small molecules: Additive benefits
- Autophagy enhancers: Compensate for reduced mitophagy
- Antioxidants: Address downstream oxidative stress
Parkin in Other Neurodegenerative Diseases
Alzheimer's Disease
While not a primary AD gene, parkin alterations are observed:
- Reduced expression: Decreased parkin in AD brain
- Aggregate sequestration: Parkin trapped in tangles/plaques
- Therapeutic potential: Enhancing parkin may help clear aggregates
Huntington's Disease
Parkin interactions with mutant huntingtin:
- Protective role: Parkin overexpression is protective
- Aggregate clearance: Helps clear mutant HTT
- Therapeutic target: Enhancing parkin beneficial
Amyotrophic Lateral Sclerosis
Parkin in motor neuron disease:
- Mitochondrial maintenance: Critical for motor neuron survival
- Protein quality control: Clears aggregated proteins
- Dysregulation observed: Altered parkin in ALS models
Model Systems for Parkin Research
Cellular Models
- Patient-derived iPSCs: Dopaminergic neurons with PARK2 mutations
- Knockdown cell lines: siRNA-mediated knockdowns
- CRISPR models: Isogenic controls with defined mutations
Animal Models
- Parkin knockout mice: Show subtle mitochondrial defects
- Parkin conditional knockouts: Tissue-specific deletion
- Mutant knock-in models: Patient mutation modeling
Complementary Models
- Zebrafish: Developmental studies, high-throughput screening
- Drosophila: Genetic interactions, behavioral assays
- Yeast: Basic mechanism studies
Biomarkers and Outcome Measures
Genetic Biomarkers
- Mutation identification: Carrier status, prognostic implications
- Variant interpretation: Pathogenicity assessment
- Family screening: Cascade testing
Functional Biomarkers
- Parkin activity assays: Measure E3 ligase function
- Mitophagy markers: Monitor pathway activation
- Mitochondrial function: Seahorse assays, imaging
Clinical Biomarkers
- Motor assessments: UPDRS, timing-based measures
- Non-motor scales: Cognitive, autonomic batteries
- Imaging: Dopaminergic PET, MRI
Diagnostic Considerations
- Early genetic testing: Young-onset PD (<40 years)
- Family history: Autosomal recessive pattern
- Phenotypic clues: Dystonia, good levodopa response
Treatment Approaches
- Levodopa/carbidopa: First-line symptomatic treatment
- Dopamine agonists: Adjunctive therapy
- MAO-B inhibitors: Disease modification potential
- Deep brain stimulation: For advanced cases
Long-Term Management
- Motor fluctuations: Treatment optimization
- Non-motor symptoms: Address neuropsychiatric features
- Physical therapy: Maintain function
- Genetic counseling: Family planning
Emerging Research Directions
Structural Studies
- Cryo-EM: Activated parkin conformations
- Small-angle X-ray scattering: Dynamic interactions
- Molecular dynamics: Conformational landscapes
Systems Biology Approaches
- Protein interactomics: New parkin partners
- Phosphoproteomics: Downstream signaling effects
- Metabolomics: Metabolic consequences
Clinical Trials
- Gene therapy trials: AAV-PARK2 delivery
- Small molecule trials: Parkin activators
- Cell therapy: Stem cell approaches
Conclusion
Parkin (PARK2) represents a critical nexus in mitochondrial quality control and neurodegeneration. As one of the most frequently mutated genes in autosomal recessive juvenile Parkinsonism, understanding parkin function and dysfunction provides crucial insights into PD pathogenesis. The PINK1-Parkin mitophagy pathway offers multiple therapeutic targets, and strategies to enhance parkin function—whether through small molecules, gene therapy, or combination approaches—represent promising avenues for disease-modifying treatments. Continued research into parkin's broader cellular functions, including synaptic maintenance and neuroinflammation regulation, will further illuminate its role in neuronal health and disease.
Additional Research Perspectives
Parkin and Protein Aggregate Clearance
Beyond mitochondria, parkin participates in general protein quality control:
- Aggresome targeting: Parkin helps clear cytoplasmic protein aggregates
- ERAD regulation: Links ER stress to protein clearance
- Lysosomal coordination: Works with autophagosomal pathways
Parkin influences cellular metabolism:
- ATP production: Maintains mitochondrial function for energy
- Calcium handling: Regulates mitochondrial calcium uptake
- Iron metabolism: Affects cellular iron homeostasis
Developmental Roles
Parkin has functions beyond adult neuronal maintenance:
- Developmental apoptosis: Regulates programmed cell death during development
- Synapse formation: Guides synaptic development and refinement
- Neuronal migration: Affects neuronal positioning in the brain
Pathway Diagram
The following diagram shows the key molecular relationships involving PARK2 - Parkin discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)